Boscheinen, Oliver,Dreyer, Matthias,Habermann, Paul,Schaefer, Hans-Ludwig,Sommerfeld, Mark,Langer, Thomas
申请号:
AU2013311777
公开号:
AU2013311777A1
申请日:
2013.09.04
申请国别(地区):
AU
年份:
2015
代理人:
摘要:
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.